ArticleClinical and translational radiation oncology2026
Early adverse events and patient-reported outcomes after salvage radiotherapy following prostatectomy according to fractionation schedule: Interim analysis of the phase III URONCOR 06-24 trial.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05781217 (Short Versus Long-term Androgen Deprivation Therapy Combined With Salvage Radiotherapy in Prostate Cancer Patients With Biochemical Recurrence After Prostatectomy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Short Versus Long-term Androgen Deprivation Therapy Combined With Salvage Radiotherapy in Prostate Cancer Patients With Biochemical Recurrence After Prostatectomy: a Multicentre Phase III Randomised Controlled Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Moderate hypofractionation is increasingly used in salvage radiotherapy (SRT) after radical prostatectomy, although prospective data in the postoperative setting remain limited. We evaluated early adverse events and patient-reported outcomes (PROs) according to fractionation schedule within a prospective multicenter phase III trial. Materials and methods: This prespecified interim analysis included the first 250 patients enrolled in the URONCOR 06-24 randomized trial (NCT05781217). SRT was delivered using moderate hypofractionation ( Results: With a median follow-up of 12.7 months, grade ≥ 2 genitourinary (GU) adverse events occurred in 21.7% of patients treated with hypofractionation versus 17.3% with conventional fractionation ( Conclusion: Early adverse events after SRT were low and comparable between fractionation schedules, and moderate hypofractionation showed a similar safety profile despite more frequent pelvic irradiation. However, given the non-randomized nature of the fractionation schedules, longer follow-up and robust adjustment for treatment-selection biases are needed before drawing definitive conclusions regarding comparative safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.